Need of robust Regulatory Intelligence Process
Quick Launch …? Many large and medium biopharma companies operate in 140-160 countries. It’s a highly challenging task to meet with regulatory requirements for product approval for new and generic drug fillings, assure regulatory abidance, and maintain a lifecycle of regulatory authorizations and established standards in these countries. A strong enough regulatory intelligence programs can help biopharma companies to effectively use regulatory data from concerned health authority to make systems up to date. Since regulatory information is available with locally operating partners of global biopharma companies, it is also important to study, place and break down applicable regulatory summary across these partners. This month update describes over a program for collecting data to give a regulatory intelligence. Unified with a standard template or visceral system, such a procedure can cut down time lag in finding for widely disseminated regulatory information, as result derogating...